| First Author | Hanks BA | Year | 2013 |
| Journal | J Clin Invest | Volume | 123 |
| Issue | 9 | Pages | 3925-40 |
| PubMed ID | 23925295 | Mgi Jnum | J:201617 |
| Mgi Id | MGI:5514468 | Doi | 10.1172/JCI65745 |
| Citation | Hanks BA, et al. (2013) Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 123(9):3925-40 |
| abstractText | Cancers subvert the host immune system to facilitate disease progression. These evolved immunosuppressive mechanisms are also implicated in circumventing immunotherapeutic strategies. Emerging data indicate that local tumor-associated DC populations exhibit tolerogenic features by promoting Treg development; however, the mechanisms by which tumors manipulate DC and Treg function in the tumor microenvironment remain unclear. Type III TGF-beta receptor (TGFBR3) and its shed extracellular domain (sTGFBR3) regulate TGF-beta signaling and maintain epithelial homeostasis, with loss of TGFBR3 expression promoting progression early in breast cancer development. Using murine models of breast cancer and melanoma, we elucidated a tumor immunoevasion mechanism whereby loss of tumor-expressed TGFBR3/sTGFBR3 enhanced TGF-beta signaling within locoregional DC populations and upregulated both the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) in plasmacytoid DCs and the CCL22 chemokine in myeloid DCs. Alterations in these DC populations mediated Treg infiltration and the suppression of antitumor immunity. Our findings provide mechanistic support for using TGF-beta inhibitors to enhance the efficacy of tumor immunotherapy, indicate that sTGFBR3 levels could serve as a predictive immunotherapy biomarker, and expand the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment. |
